

Advice on the use of masks in the context of COVID-19

Interim guidance

5 June 2020



This document is an update of the guidance published on 6 April 2020 and includes updated scientific evidence relevant to the use of masks for preventing transmission of Coronavirus disease 2019 (COVID-19) as well as practical considerations. The main differences from the previous version include the following:

- Updated information on transmission from symptomatic, pre-symptomatic and asymptomatic people infected with COVID-19, as well as an update of the evidence of all sections of this document;
- New guidance on the targeted continuous use of medical masks by health workers working in clinical areas in health facilities in geographical areas with community transmission¹ of COVID-19;
- Updated guidance and practical advice for decision-makers on the use of medical and non-medical masks by the general public using a risk-based approach;
- New guidance on non-medical mask features and characteristics, including choice of fabric, number and combination of layers, shape, coating and maintenance.

Guidance and recommendations included in this document are based on previous WHO guidelines (in particular the WHO Guidelines on infection prevention and control of epidemic- and pandemic-prone acute respiratory infections in health care) (1) and the evaluation of current evidence by the WHO ad hoc COVID-19 IPC Guidance Development Group (COVID-19 IPC GDG) that meets at least once a week. The process of interim guidance development during emergencies consists of a transparent and robust process of evaluation of the available evidence on benefits and harms, synthesized through expedited systematic reviews and expert consensus-building facilitated by methodologists. This process also considers, as much as possible, potential resource implications, values and preferences, feasibility, equity, ethics and research gaps.

Purpose of the guidance

This document provides guidance to decision makers, public health and IPC professionals, health care managers, and health workers on the use of medical and non-medical masks in health care (including long-term care and residential

settings, for the general public, and during home care. It will be revised as more data become available.

Background

The use of masks is part of a comprehensive package of the prevention and control measures that can limit the spread of certain respiratory viral diseases, including COVID-19. Masks can be used either for protection of healthy persons (worn to protect oneself when in contact with an infected individual) or for source control (worn by an infected individual to prevent onward transmission).

However, the use of a mask alone is insufficient to provide an adequate level of protection or source control, and other personal and community level measures should also be adopted to suppress transmission of respiratory viruses. Whether or not masks are used, compliance with hand hygiene, physical distancing and other infection prevention and control (IPC) measures are critical to prevent human-to-human transmission of COVID-19.

This document provides information and guidance on the use of masks in health care settings, for the general public, and during home care. The World Health Organization (WHO) has developed specific guidance on IPC strategies for health care settings (2), long-term care facilities (LTCF) (3), and home care.(4)

Transmission of COVID-19

Knowledge about transmission of the COVID-19 virus is accumulating every day. COVID-19 is primarily a respiratory disease and the spectrum of infection with this virus can range from people with very mild, non-respiratory symptoms to severe acute respiratory illness, sepsis with organ dysfunction and death. Some people infected have reported no symptoms at all.

According to the current evidence, COVID-19 virus is primarily transmitted between people via respiratory droplets and contact routes. Droplet transmission occurs when a person is in close contact (within 1 metre) with an infected person and exposure to potentially infective respiratory droplets occurs, for example, through coughing, sneezing or very close personal contact resulting in the inoculation of entry portals such as the mouth, nose or conjunctivae

¹ Defined by WHO as “experiencing larger outbreaks of local transmission defined through an assessment of factors including, but not limited to: large numbers of cases not linkable to transmission chains; large numbers of cases from sentinel

surveillance; and/or multiple unrelated clusters in several areas of the country/territory/area” (<https://www.who.int/publications-detail/global-surveillance-for-covid-19-caused-by-human-infection-with-covid-19-virus-interim-guidance>)

(eyes).(5-10) Transmission may also occur through fomites in the immediate environment around the infected person.(11, 12) Therefore, transmission of the COVID-19 virus can occur directly by contact with infected people, or indirectly by contact with surfaces in the immediate environment or with objects used on or by the infected person (e.g., stethoscope or thermometer).

In specific circumstances and settings in which procedures that generate aerosols are performed, airborne transmission of the COVID-19 virus may be possible. The scientific community has been discussing whether the COVID-19 virus, might also spread through aerosols in the absence of aerosol generating procedures (AGPs). This is an area of active research. So far, air sampling in clinical settings where AGPs were not performed, found virus RNA in some studies (13-15) but not in others. (11, 12, 16) However, the presence of viral RNA is not the same as replication- and infection-competent (viable) virus that could be transmissible and capable of sufficient inoculum to initiate invasive infection. Furthermore, a small number of experimental studies conducted in aerobiology laboratories have found virus RNA (17) and viable virus (18), but these were experimentally induced AGPs where aerosols were generated using high-powered jet nebulizers and do not reflect normal human cough conditions. High quality research including randomized trials in multiple settings are required to address many of the acknowledged research gaps related to AGPs and airborne transmission of the COVID-19 virus.

Current evidence suggests that most transmission of COVID-19 is occurring from symptomatic people to others in close contact, when not wearing appropriate PPE. Among symptomatic patients, viral RNA can be detected in samples weeks after the onset of illness, but viable virus was not found after day 8 post onset of symptoms (19, 20) for mild patients, though this may be longer for severely ill patients. Prolonged RNA shedding, however, does not necessarily mean continued infectiousness. Transmissibility of the virus depends on the amount of viable virus being shed by a person, whether or not they are coughing and expelling more droplets, the type of contact they have with others, and what IPC measures are in place. Studies that investigate transmission should be interpreted bearing in mind the context in which they occurred.

There is also the possibility of transmission from people who are infected and shedding virus but have not yet developed symptoms; this is called pre-symptomatic transmission. The incubation period for COVID-19, which is the time between exposure to the virus and symptom onset, is on average 5-6 days, but can be as long as 14 days.(21, 22) Additionally, data suggest that some people can test positive for COVID-19, via polymerase chain reaction (PCR) testing 1-3 days before they develop symptoms.(23) Pre-symptomatic transmission is defined as the transmission of the COVID-19 virus from someone infected and shedding virus but who has not yet developed symptoms. People who develop symptoms appear to have higher viral loads on or just prior to the day of symptom onset, relative to later on in their infection.(24)

Some people infected with the COVID-19 virus do not ever develop any symptoms, although they can shed virus which may then be transmitted to others. One recent systematic review found that the proportion of asymptomatic cases ranged from 6% to 41%, with a pooled estimate of 16%

(12%–20%),(25) although most studies included in this review have important limitations of poor reporting of symptoms, or did not properly define which symptoms they were investigating. Viable virus has been isolated from specimens of pre-symptomatic and asymptomatic individuals, suggesting, therefore, that people who do not have symptoms may be able to transmit the virus to others.(26) Comprehensive studies on transmission from asymptomatic individuals are difficult to conduct, but the available evidence from contact tracing reported by Member States suggests that asymptotically-infected individuals are much less likely to transmit the virus than those who develop symptoms.

Among the available published studies, some have described occurrences of transmission from people who did not have symptoms.(21,25-32) For example, among 63 asymptotically-infected individuals studied in China, there was evidence that 9 (14%) infected another person.(31) Furthermore, among two studies which carefully investigated secondary transmission from cases to contacts, one found no secondary transmission among 91 contacts of 9 asymptomatic cases,(33) while the other reported that 6.4% of cases were attributable to pre-symptomatic transmission.(32) The available data, to date, on onward infection from cases without symptoms comes from a limited number of studies with small samples that are subject to possible recall bias and for which fomite transmission cannot be ruled out.

Guidance on the use of masks in health care settings (including long-term care and residential facilities)

Use of medical masks and respirators to provide care to suspected or confirmed COVID-19 patients

This section provides evidence- and consensus-based guidance on the use of medical masks and respirators by health workers providing direct care to COVID-19 patients.

Definitions

Medical masks are defined as surgical or procedure masks that are flat or pleated; they are affixed to the head with straps that go around the ears or head or both. Their performance characteristics are tested according to a set of standardized test methods (ASTM F2100, EN 14683, or equivalent) that aim to balance high filtration, adequate breathability and optionally, fluid penetration resistance.(34, 35)

Filtering facepiece respirators (FFR), or respirators, similarly offer a balance of filtration and breathability; however, whereas medical masks filter 3 micrometre droplets, respirators must filter more challenging 0.075 micrometre solid particles. European FFRs, according to standard EN 149, at FFP2 performance filter at least 94% solid NaCl particles and oil droplets, and US N95 FFRs, according to NIOSH 42 CFR Part 84, filter at least 95% NaCl particles. Certified FFRs must also ensure unhindered breathing with maximum resistances during inhalation and exhalation. Another important difference is the way filtration is tested; medical mask filtration tests are performed on a cross-section of the masks whereas FFRs are tested for filtration across the entire surface. Therefore, the layers of the filtration material and the FFR shape, ensuring outer edges of the FFR seal around wearer's face, result in a guaranteed claimed filtration when worn compared to the open shape, or leaking structure, of medical masks. Other FFR performance requirements include being within specified parameters for maximum CO₂ build up, total inward leakage and tensile strength of straps.(36, 37)

Available evidence

WHO's guidance on the type of respiratory protection to be worn by health workers providing direct care to COVID-19 patients is based on 1) WHO guidelines recommendations on IPC of epidemic- and pandemic-prone acute respiratory infections in health care;(1) 2) updated systematic reviews of randomized controlled trials on the effectiveness of medical masks compared to that of respirators on the risk of: clinical respiratory illness, influenza-like illness (ILI) and laboratory-confirmed influenza or viral infections. The WHO guidance is similar to recent guidelines of other professional organizations (the European Society of Intensive Care Medicine and the Society of Critical Care Medicine, and the Infectious Diseases Society of America).(38, 39)

Meta-analyses in systematic literature reviews have reported that the use of N95 respirators compared with the use of medical masks is not associated with any statistically significant lower risk of the clinical respiratory illness outcomes or laboratory-confirmed influenza or viral infections.(40, 41) Low-certainty evidence from a systematic review of observational studies related to the betacoronaviruses that cause severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) and COVID-19 showed that the use of face protection (including respirators and medical masks) results in a large reduction in risk of infection among health workers; N95 or similar respirators might be associated with greater reduction in risk than medical or 12–16-layer cotton masks), but the studies had important limitations (recall bias, limited information about the situations when respirators were used and about measurement of exposures) and most were conducted in settings in which AGPs were performed.(42)

WHO continues gathering scientific data and evidence on the effectiveness of different masks use and on its potential harms, risks and disadvantages, as well as its combination with hand hygiene, physical distancing and other IPC measures.

Recommendations

The WHO COVID-19 IPC GDG considered all available evidence on the COVID-19 virus modes of transmission and on medical mask versus respirator use to protect health workers from infection, its level of certainty, as well as the potential benefits and harms, such as development of facial skin lesions, irritant dermatitis or worsening acne, or breathing difficulties that are more frequent with respirators.(43, 44)

The GDG also considered the implications of maintaining or changing the current recommendations, in terms of availability of medical masks versus respirators, cost and procurement implications, feasibility, equity of access to these respiratory protections by health workers around the world. The GDG acknowledged that in general, health

workers have strong preferences regarding highest perceived protection possible to prevent COVID-19 infection and, therefore, place high value on the potential benefits of respirators in settings without AGPs, despite demonstration of equivalence of effectiveness compared to medical masks in some studies and low certainty of the evidence suggesting their greater risk reduction in others.

Definitions

Universal masking in health facilities is defined as the requirement to wear a mask by all health workers and anyone entering the facility, no matter what activities are undertaken (discussed with COVID-19 IPC GDG).

Targeted continuous medical mask use is defined here as the practice of wearing a medical mask by all health workers and caregivers working in clinical areas during all routine activities throughout the entire shift. In this context, masks are only changed if they become soiled, wet or damaged, or if the health worker/caregiver removes the mask (e.g. for eating or drinking or caring for a patient who requires droplet/contact precautions for other reasons) (discussed with COVID-19 IPC GDG).

Health workers are all people primarily engaged in actions with the primary intent of enhancing health. Examples are: Nursing and midwifery professionals, doctors, cleaners, other staff who work in health facilities, social workers, and community health workers, etc. (46)

In conclusion, the great majority of the GDG members confirmed previous recommendations issued by WHO which include that:

- in the absence of AGPs², WHO recommends that health workers providing direct care to COVID-19 patients, should wear a medical mask (in addition to other PPE that are part of droplet and contact precautions);
- in care settings for COVID-19 patients where AGPs are performed (e.g. COVID-19 intensive and semi-intensive care units), WHO recommends that health workers should wear a respirator (N95 or FFP2 or FFP3 standard, or equivalent).

Note: Respirators are recommended for settings where AGPs are performed. Based on values and preferences and if widely available, they could also be used when providing direct care to COVID-19 patients in other settings. For additional guidance on PPE, including PPE beyond mask use by health workers, see WHO IPC guidance during health care when COVID-19 infection is suspected (2) and also WHO guidance on the rational use of PPE.(45)

² The WHO list of AGPs includes: tracheal intubation, non-invasive ventilation, tracheotomy, cardiopulmonary resuscitation, manual ventilation before intubation,

bronchoscopy, sputum induction induced by using nebulized hypertonic saline, and autopsy procedures.

Targeted continuous medical mask use by health workers in areas of known or suspected COVID-19 community transmission

This section considers the continuous use of medical masks by health workers and caregivers in areas of known or suspected community transmission regardless of whether direct care to COVID-19 patients is being provided.

Available evidence

In areas where there is community transmission or large-scale outbreaks of COVID-19, universal masking has been adopted in many hospitals to reduce the potential of (asymptomatic, pre-symptomatic and symptomatic) transmission by health workers and anyone entering the facility with COVID-19 to other health workers and to patients.(47)

There are currently no studies that have evaluated the effectiveness and potential adverse effects of universal or targeted continuous mask use by health workers in preventing transmission of SARS-CoV-2. Despite the lack of evidence the great majority of the WHO COVID-19 IPC GDG members supports the practice of health workers and caregivers in clinical areas (irrespective of whether there are COVID-19 or other patients in the clinical areas) in geographic settings where there is known or suspected community transmission of COVID-19, to continuously wear a medical mask throughout their shift, apart from when eating and drinking or changing the mask after caring for a patient requiring droplet/contact precautions for other reasons (e.g., influenza), to avoid any possibility of cross-transmission.

This practice reflects the strong preferences and values placed on preventing potential COVID-19 infections in health workers and in non-COVID-19 patients; these preferences and values may outweigh both the potential discomfort and other negative consequences of continuously wearing a medical mask throughout their shift and the current lack of evidence.

Note: Decision makers should consider the transmission intensity in the catchment area of the health facility and the feasibility of implementing a policy of continuous mask use for all health workers compared to a policy based on assessed or presumed exposure risk. Either way, procurement and costs should be taken into account and planned. When planning masks for all health workers, long-term availability of medical masks for all workers should be ensured, in particular for those providing care to confirmed or suspected COVID-19 patients.

Guidance

In the context of locations/areas with known or suspected community transmission or intense outbreaks of COVID-19, WHO provides the following guidance:

- Health workers, including community health workers and caregivers, who work in clinical areas should continuously wear a medical mask during their routine activities throughout the entire shift; apart from when eating and drinking and changing their medical mask after caring for a patient who requires droplet/contact precautions for other reasons;
- According to expert opinion, it is particularly important to adopt the continuous use of masks in potential higher

transmission risk areas including triage, family physician/GP practices, outpatient departments, emergency rooms, COVID-19 specified units, haematological, cancer, transplant units, long-term health and residential facilities;

- When using medical masks throughout the entire shift, health workers should make sure that:
 - the medical mask is changed when wet, soiled, or damaged;
 - the medical mask is not touched to adjust it or displaced from the face for any reason; if this happens, the mask should be safely removed and replaced; and hand hygiene performed;
 - the medical mask (as well as other personal protective equipment) is discarded and changed after caring for any patient on contact/droplet precautions for other pathogens;
- Staff who do not work in clinical areas do not need to use a medical mask during routine activities (e.g., administrative staff);
- Masks should not be shared between health workers and should be appropriately disposed of whenever removed and not reused;
- A particulate respirator at least as protective as a US National Institute for Occupational Safety and Health-certified N95, N99, US FDA surgical N95, European Union standard FFP2 or FFP3, or equivalent, should be worn in settings for COVID-19 patients where AGPs are performed (see WHO recommendations above). In these settings, this includes its continuous use by health workers throughout the entire shift, when this policy is implemented.

To be fully effective, continuous wearing of a medical mask by health workers, throughout their entire shift, should be implemented along with other measures to reinforce frequent hand hygiene and physical distancing among health workers in shared and crowded places where mask use may be unfeasible such as cafeterias, dressing rooms, etc.

The following **potential harms and risks** should be carefully taken into account when adopting this approach of targeted continuous medical mask use, including:

- self-contamination due to the manipulation of the mask by contaminated hands;(48, 49)
- potential self-contamination that can occur if medical masks are not changed when wet, soiled or damaged;
- possible development of facial skin lesions, irritant dermatitis or worsening acne, when used frequently for long hours(43, 44, 50)
- masks may be uncomfortable to wear;(41, 51)
- false sense of security, leading to potentially less adherence to well recognized preventive measures such as physical distancing and hand hygiene;
- risk of droplet transmission and of splashes to the eyes, if mask wearing is not combined with eye protection;
- disadvantages for or difficulty wearing them by specific vulnerable populations such as those with mental health disorders, developmental disabilities, the deaf and hard of hearing community, and children;
- difficulty wearing them in hot and humid environments.

Table 1. Type of mask for use by health workers depending on transmission scenario, setting and activity*

COVID-19 Transmission scenario	Who	Setting	Activity	What type of mask*
Known or suspected community transmission	Health worker or caregiver	Health facility (including primary, secondary, tertiary care levels, outpatient care, and LTCF)	In patient care area – irrespective if patients are COVID-19 suspect/confirmed	Medical mask (targeted continuous medical masking)
	Personnel (working in health care facilities but not providing care for patients, e.g. administrative staff)	Health care facility (including primary, secondary, tertiary care levels, outpatient care, and LTCF)	No routine activities in patient areas	Medical mask not needed. Medical mask should be considered only if in contact or within 1m of patients, or according to local risk assessment.
	Health worker	Home visit (for example, for antenatal or postnatal care, or for a chronic condition)	When in direct contact or when a distance of at least 1m cannot be maintained.	Consider using a medical mask
	Health worker	Community	Community outreach programs	Consider using a medical mask
Sporadic transmission or clusters of COVID-19 cases	Health worker or caregiver	Health care facility (including primary, secondary, tertiary care levels, outpatient care, and LTCF)	Providing any patient care	Medical mask use according to standard and transmission-based precautions (risk assessment)
	Health worker	Community	Community outreach programs	No mask needed
Any transmission scenario	Health worker or caregiver	Health care facility (including primary, secondary, tertiary care levels, outpatient care, and LTCF)	When in contact with suspect or confirmed COVID-19 patient	Medical mask
	Health worker	Health care facility (including LTCF), in settings where aerosol generating procedures (AGP) are performed	Performing an AGP on a suspected or confirmed COVID-19 patient or providing care in a setting where AGPs are in place for COVID-19 patients.	Respirator (N95 or N99 or FFP2 or FFP3)
	Health worker or caregiver	Home care	When in close contact or when a distance of at least 1 m cannot be maintained from a suspect or confirmed COVID-19 patient	Medical mask

*This table refers only to the use of medical masks and respirators. The use of medical masks and respirators may need to be combined with other personal protective equipment and other measures as appropriate, and always with hand hygiene.

Alternatives to medical masks in health facilities:

In the context of severe medical mask shortage, face shields may be considered as an alternative. The use of cloth masks (referred to as fabric masks in this document) as an alternative to medical masks is not considered appropriate for protection of health workers based on limited available evidence. One study that evaluated the use of cloth masks in a health care facility found that health care workers using cotton cloth masks were at increased risk of influenza like illness compared with those who wore medical masks.(52)

As for other PPE items, if production of cloth masks for use in health care settings is proposed locally in situations of shortage or stock out, a local authority should assess the proposed PPE according to specific minimum standards and technical specifications.

Additional considerations for community care settings:

Community health workers should use standard precautions for all patients at all times, with particular emphasis regarding hand and respiratory hygiene, surface and environmental cleaning and disinfection, and the appropriate use of personal protective equipment. Additional IPC measures that are needed will depend on the local COVID-19 transmission dynamics and the type of contact required by the health care activity. Furthermore, the community health workforce should ensure that patients and workforce members apply respiratory hygiene, and physical distancing of at least 1 metre (3.3 feet). They also may support set-up, community education and maintenance of hand hygiene stations.(53) When conducting screening activities (e.g., conducting interviews), no mask is needed if a distance of at least 1 metre (3.3 feet) can be maintained and there is no direct contact with patients.(42, 53) In the context of known or suspected

community transmission, consider additional precautions, including the wearing of a medical mask, when community health workers provide essential routine services (Table 2).

When a patient is suspected or confirmed to have COVID-19 infection, community health workers should use contact and droplet precautions. Contact and droplet precautions include the use of a medical mask, gown, gloves and eye protection.(53)

Guidance on the use of masks for the general public

Available evidence

Studies of influenza, influenza-like illness, and human coronaviruses (not including COVID-19) provide evidence that the use of a medical mask can prevent the spread of infectious droplets from a symptomatic infected person (source control) to someone else and potential contamination of the environment by these droplets.(54, 55) There is limited evidence that wearing a medical mask by healthy individuals in households, in particular those who share a house with a sick person, or among attendees of mass gatherings may be beneficial as a measure preventing transmission.(41, 56-61) A recent meta-analysis of these observational studies, with the intrinsic biases of observational data, showed that either disposable surgical masks or reusable 12–16-layer cotton masks were associated with protection of healthy individuals within households and among contacts of cases.(42)

This could be considered to be indirect evidence for the use of masks (medical or other) by healthy individuals in the wider community; however, these studies suggest that such individuals would need to be in close proximity to an infected person in a household or at a mass gathering where physical distancing cannot be achieved, to become infected with the virus.

Results from cluster randomized controlled trials on the use of masks among young adults living in university residences in the United States of America indicate that face masks may reduce the rate of influenza-like illness, but showed no impact on risk of laboratory-confirmed influenza.(62, 63) **At present, there is no direct evidence (from studies on COVID-19 and in healthy people in the community) on the effectiveness of universal masking of healthy people in the community to prevent infection with respiratory viruses, including COVID-19.**

WHO regularly monitors all emerging evidence about this important topic and will provide updates as more information becomes available.

Guidance

1) WHO recommends that persons with any symptoms suggestive of COVID-19 should (1, 2):

- wear a medical mask, self-isolate, and seek medical advice as soon as they start to feel unwell with potential symptoms of COVID-19, even if symptoms are mild. Symptoms can include: fever, cough, fatigue, loss of appetite, shortness of breath and muscle pain. Other non-specific symptoms such as sore throat, nasal congestion, headache, diarrhoea, nausea and vomiting, have also been reported. Loss of smell and taste preceding the onset of respiratory symptoms have also been

reported.(64, 65) Older people and immunosuppressed patients may present with atypical symptoms such as fatigue, reduced alertness, reduced mobility, diarrhoea, loss of appetite, delirium, and absence of fever.(26, 66, 67) It is important to note that early symptoms for some people infected with COVID-19 may be very mild and unspecific;

- follow instructions on how to put on, take off, and dispose of medical masks and perform hand hygiene;(68)
- follow all additional measures, in particular respiratory hygiene, frequent hand hygiene and maintaining physical distance of at least 1 metre (3.3 feet) from other persons.(42)

In the context of the COVID-19 pandemic, it is recommended that all persons, regardless of whether they are using masks or not, should:

- avoid groups of people and crowded spaces (follow local advice);
- maintain physical distance of at least 1 metre (3.3 feet) from other persons, especially from those with respiratory symptoms (e.g. coughing, sneezing);
- perform hand hygiene frequently, using an alcohol-based handrub if hands are not visibly dirty or soap and water;
- use respiratory hygiene i.e. cover their nose and mouth with a bent elbow or paper tissue when coughing or sneezing, dispose of the tissue immediately after use, and perform hand hygiene;
- refrain from touching their mouth, nose, and eyes.

2) Advice to decision makers on the use of masks for the general public

Many countries have recommended the use of fabric masks/face coverings for the general public. At the present time, the widespread use of masks by healthy people in the community setting is not yet supported by high quality or direct scientific evidence and there are potential benefits and harms to consider (see below).

However, taking into account the available studies evaluating pre- and asymptomatic transmission, a growing compendium of observational evidence on the use of masks by the general public in several countries, individual values and preferences, as well as the difficulty of physical distancing in many contexts, WHO has updated its guidance to advise that to prevent COVID-19 transmission effectively in areas of community transmission, governments should encourage the general public to wear masks in specific situations and settings as part of a comprehensive approach to suppress SARS-CoV-2 transmission (Table 2).

WHO advises decision makers to apply a risk-based approach focusing on the following criteria when considering or encouraging the use of masks for the general public:

1. **Purpose** of mask use: if the intention is preventing the infected wearer transmitting the virus to others (that is, source control) and/or to offer protection to the healthy wearer against infection (that is, prevention).

2. Risk of **exposure** to the COVID-19 virus
 - due to epidemiology and intensity of transmission in the population: if there is community transmission and there is limited or no capacity to implement other containment measures such as contact tracing, ability to carry out testing and isolate and care for suspected and confirmed cases.
 - depending on occupation: e.g., individuals working in close contact with the public (e.g., social workers, personal support workers, cashiers).
3. **Vulnerability** of the mask wearer/population: for example, medical masks could be used by older people, immunocompromised patients and people with comorbidities, such as cardiovascular disease or diabetes mellitus, chronic lung disease, cancer and cerebrovascular disease.(69)
4. **Setting** in which the population lives: settings with high population density (e.g. refugee camps, camp-like settings, those living in cramped conditions) and settings

where individuals are unable to keep a physical distance of at least 1 metre (3.3 feet) (e.g. public transportation).

5. **Feasibility:** availability and costs of masks, access to clean water to wash non-medical masks, and ability of mask wearers to tolerate adverse effects of wearing a mask.
6. **Type** of mask: medical mask versus non-medical mask

Based on these criteria, Table 2 provides practical examples of situations where the general public should be encouraged to wear a mask and it indicates specific target populations and the type of mask to be used according to its purpose. The decision of governments and local jurisdictions whether to recommend or make mandatory the use of masks should be based on the above criteria, and on the local context, culture, availability of masks, resources required, and preferences of the population.

Table 2. Examples of where the general public should be encouraged to use medical and non-medical masks in areas with known or suspected community transmission

Situations/settings	Population	Purpose of mask use	Type of mask to consider wearing if recommended locally
Areas with known or suspected widespread transmission and limited or no capacity to implement other containment measures such as physical distancing, contact tracing, appropriate testing, isolation and care for suspected and confirmed cases.	General population in public settings, such as grocery stores, at work, social gatherings, mass gatherings, closed settings, including schools, churches, mosques, etc.	Potential benefit for source control	Non-medical mask
Settings with high population density where physical distancing cannot be achieved; surveillance and testing capacity, and isolation and quarantine facilities are limited	People living in cramped conditions, and specific settings such as refugee camps, camp-like settings, slums	Potential benefit for source control	Non-medical mask
Settings where a physical distancing cannot be achieved (close contact)	General public on transportation (e.g., on a bus, plane, trains) Specific working conditions which places the employee in close contact or potential close contact with others e.g., social workers, cashiers, servers	Potential benefit for source control	Non-medical mask
Settings where physical distancing cannot be achieved and increased risk of infection and/or negative outcomes	Vulnerable populations: <ul style="list-style-type: none"> • People aged ≥ 60 years • People with underlying comorbidities, such as cardiovascular disease or diabetes mellitus, chronic lung disease, cancer, cerebrovascular disease, immunosuppression 	Protection	Medical mask
Any setting in the community*	Persons with any symptoms suggestive of COVID-19	Source control	Medical mask

*This applies to any transmission scenario

Potential benefits/advantages

The likely advantages of the use of masks by healthy people in the general public include:

- reduced potential exposure risk from infected persons before they develop symptoms;

- reduced potential stigmatization of individuals wearing masks to prevent infecting others (source control) or of people caring for COVID-19 patients in non-clinical settings;(70)
- making people feel they can play a role in contributing to stopping spread of the virus;

- reminding people to be compliant with other measures (e.g., hand hygiene, not touching nose and mouth). However, this can also have the reverse effect (see below);
- potential social and economic benefits. Amidst the global shortage of surgical masks and PPE, encouraging the public to create their own fabric masks may promote individual enterprise and community integration. Moreover, the production of non-medical masks may offer a source of income for those able to manufacture masks within their communities. Fabric masks can also be a form of cultural expression, encouraging public acceptance of protection measures in general. The safe re-use of fabric masks will also reduce costs and waste and contribute to sustainability.

Potential harms/disadvantages

The likely disadvantages of the use of mask by healthy people in the general public include:

- potential increased risk of self-contamination due to the manipulation of a face mask and subsequently touching eyes with contaminated hands;(48, 49)
- potential self-contamination that can occur if non-medical masks are not changed when wet or soiled. This can create favourable conditions for microorganism to amplify;
- potential headache and/or breathing difficulties, depending on type of mask used;
- potential development of facial skin lesions, irritant dermatitis or worsening acne, when used frequently for long hours;(50)
- difficulty with communicating clearly;
- potential discomfort;(41, 51)
- a false sense of security, leading to potentially lower adherence to other critical preventive measures such as physical distancing and hand hygiene;
- poor compliance with mask wearing, in particular by young children;
- waste management issues; improper mask disposal leading to increased litter in public places, risk of contamination to street cleaners and environment hazard;
- difficulty communicating for deaf persons who rely on lip reading;
- disadvantages for or difficulty wearing them, especially for children, developmentally challenged persons, those with mental illness, elderly persons with cognitive impairment, those with asthma or chronic respiratory or breathing problems, those who have had facial trauma or recent oral maxillofacial surgery, and those living in hot and humid environments.

If masks are recommended for the general public, the decision-maker should:

- clearly communicate the purpose of wearing a mask, where, when, how and what type of mask should be worn. Explain what wearing a mask may achieve and what it will not achieve, and communicate clearly that this is one part of a package of measures along with hand hygiene, physical distancing and other measures that are all necessary and all reinforce each other;
- inform/train people on when and how to use masks safely (see mask management and maintenance sections), i.e. put on, wear, remove, clean and dispose;

- consider the feasibility of use, supply/access issues, social and psychological acceptance (of both wearing and not wearing different types of masks in different contexts);
- continue gathering scientific data and evidence on the effectiveness of mask use (including different types and makes as well as other face covers such as scarves) in non-health care settings;
- evaluate the impact (positive, neutral or negative) of using masks in the general population (including behavioral and social sciences).

WHO encourages countries and community adopting policies on masks use in the general public to conduct good quality research to assess the effectiveness of this intervention to prevent and control transmission.

3) Types of mask to consider

Medical mask

Medical masks should be certified according to international or national standards to ensure they offer predictable product performance when used by health workers, according to the risk and type of procedure performed in a health care setting. Designed for single use, a medical mask's initial filtration (at least 95% droplet filtration), breathability and, if required, fluid resistance are attributed to the type (e.g. spunbond or meltblown) and layers of manufactured non-woven materials (e.g. polypropylene, polyethylene or cellulose). Medical masks are rectangular in shape and comprise three or four layers. Each layer consists of fine to very fine fibres. These masks are tested for their ability to block droplets (3 micrometres in size; EN 14683 and ASTM F2100 standards) and particles (0.1 micrometre in size; ASTM F2100 standard only). The masks must block droplets and particles while at the same time they must also be breathable by allowing air to pass. Medical masks are regulated medical devices and categorized as PPE.

The use of medical masks in the community may divert this critical resource from the health workers and others who need them the most. In settings where medical masks are in short supply, **medical masks should be reserved for health workers and at-risk individuals when indicated.**

Non-medical mask

Non-medical (also referred to as "fabric" in this document) masks are made from a variety of woven and non-woven fabrics, such as polypropylene. Non-medical masks may be made of different combinations of fabrics, layering sequences and available in diverse shapes. Few of these combinations have been systematically evaluated and there is no single design, choice of material, layering or shape among the non-medical masks that are available. The unlimited combination of fabrics and materials results in variable filtration and breathability.

A non-medical mask is neither a medical device nor personal protective equipment. However, a non-medical mask standard has been developed by the French Standardization Association (AFNOR Group) to define minimum performance in terms of filtration (minimum 70% solid particle filtration or droplet filtration) and breathability (maximum pressure difference of 0.6 mbar/cm² or maximum

inhalation resistance of 2.4 mbar and maximum exhalation resistance of 3 mbar).(71)

The lower filtration and breathability standardized requirements, and overall expected performance, indicate that the use of non-medical masks, made of woven fabrics such as cloth, and/or non-woven fabrics, should only be considered for source control (used by infected persons) in community settings and not for prevention. They can be used ad-hoc for specific activities (e.g., while on public transport when physical distancing cannot be maintained), and their use should always be accompanied by frequent hand hygiene and physical distancing.

Decision makers advising on type of non-medical mask should take into consideration the following features of non-medical masks: filtration efficiency (FE), or filtration, breathability, number and combination of material used, shape, coating and maintenance.

a) Type of materials: filtration efficiency (FE), breathability of single layers of materials, filter quality factor

The selection of material is an important first step as the filtration (barrier) and breathability varies depending on the fabric. Filtration efficiency is dependent on the tightness of the weave, fibre or thread diameter, and, in the case of non-woven materials, the manufacturing process (spunbond, meltblown, electrostatic charging).(49, 72) The filtration of

cloth fabrics and masks has been shown to vary between 0.7% and 60%.(73, 74) The higher the filtration efficiency the more of a barrier provided by the fabric.

Breathability is the ability to breathe through the material of the mask. Breathability is the difference in pressure across the mask and is reported in millibars (mbar) or Pascals (Pa) or, for an area of mask, over a square centimeter (mbar/cm² or Pa/cm²). Acceptable breathability of a medical mask should be below 49 Pa/cm². For non-medical masks, an acceptable pressure difference, over the whole mask, should be below 100 Pa.(73)

Depending on fabric used, filtration efficiency and breathability can complement or work against one another. Recent data indicate that two non-woven spunbond layers, the same material used for the external layers of disposable medical masks, offer adequate filtration and breathability. Commercial cotton fabric masks are in general very breathable but offer lower filtration.(75) The filter quality factor known as “Q” is a commonly used filtration quality factor; it is a function of filtration efficiency (filtration) and breathability, with higher values indicating better overall efficiency.(76) Table 3 shows FE, breathability and the filter quality factor, Q, of several fabrics and non-medical masks.(73, 77) According to expert consensus three (3) is the minimum Q factor recommended. This ranking serves as an initial guide only.

Table 3. Non-medical mask filtration efficiency, pressure drop and filter quality factor*

Material	Source	Structure	Initial Filtration Efficiency (%)	Initial Pressure drop (Pa)	Filter quality factor, Q ** (kPa ⁻¹)
Polypropylene	Interfacing material, purchased as-is	Spunbond (Nonwoven)	6	1.6	16.9
Cotton 1	Clothing (T-shirt)	Woven	5	4.5	5.4
Cotton 2	Clothing (T-shirt)	Knit	21	14.5	7.4
Cotton 3	Clothing (Sweater)	Knit	26	17	7.6
Polyester	Clothing (Toddler wrap)	Knit	17	12.3	6.8
Cellulose	Tissue paper	Bonded	20	19	5.1
Cellulose	Paper towel	Bonded	10	11	4.3
Silk	Napkin	Woven	4	7.3	2.8
Cotton, gauze	N/A	Woven	0.7	6.5	0.47
Cotton, handkerchief	N/A	Woven	1.1	9.8	0.48
Nylon	Clothing (Exercise pants)	Woven	23	244	0.4

* This table refers only to materials reported in experimental peer-reviewed studies. The filtration efficiency, pressure drop and Q factor are dependent on flow rate. ** According to expert consensus, three (3) is the minimum Q factor recommended.

It is preferable not to select elastic material for making masks; during wear, the mask material may be stretched over the face, resulting in increased pore size and lower filtration efficiency throughout use. Also, elastic materials may degrade over time and are sensitive to washing at high temperatures.

b) Number of layers

A minimum of three layers is required for non-medical masks, depending on the fabric used. The innermost layer of the mask is in contact with the wearer's face. The outermost layer is exposed to the environment.(78)

Fabric cloths (e.g., nylon blends and 100% polyester) when folded into two layers, provides 2-5 times increased filtration efficiency compared to a single layer of the same cloth, and filtration efficiency increases 2-7 times if it is folded into 4 layers.(75) Masks made of cotton handkerchiefs alone should consist of at least 4 layers, but have achieved only 13% filtration efficiency.(73) Very porous materials, such as gauze, even with multiple layers will not provide sufficient filtration; only 3% filtration efficiency.(73)

It is important to note that with more tightly woven materials, as the number of layers increases, the breathability may be

reduced. A quick check for breathability may be performed by attempting to breathe, through the mouth, and through the multiple layers.

c) Combination of material used

The ideal combination of material for non-medical masks should include three layers as follows: 1) an innermost layer of a hydrophilic material (e.g. cotton or cotton blends); 2), an outermost layer made of hydrophobic material (e.g., polypropylene, polyester, or their blends) which may limit external contamination from penetration through to the wearer's nose and mouth; 3) a middle hydrophobic layer of synthetic non-woven material such as polypropylene or a cotton layer which may enhance filtration or retain droplets.

d) Mask shape

Mask shapes include flat-fold or duckbill and are designed to fit closely over the nose, cheeks and chin of the wearer. When the edges of the mask are not close to the face and shift, for example, when speaking, internal/external air penetrates through the edges of the mask rather than being filtered through the fabric. Leaks where unfiltered air moves in and out of the mask may be attributed to the size and shape of the mask.(79)

It is important to ensure that the mask can be held in place comfortably with little adjustment using elastic bands or ties.

e) Coating of fabric

Coating the fabric with compounds like wax may increase the barrier and render the mask fluid resistant; however, such coatings may inadvertently completely block the pores and make the mask difficult to breathe through. In addition to decreased breathability unfiltered air may more likely escape the sides of the mask upon exhalation. Coating is therefore not recommended.

f) Mask maintenance

Masks should only be used by one person and should not be shared.

All masks should be changed if wet or visibly soiled; a wet mask should not be worn for an extended period of time. Remove the mask without touching the front of the mask, do not touch the eyes or mouth after mask removal. Either discard the mask or place it in a sealable bag where it is kept until it can be washed and cleaned. Perform hand hygiene immediately afterwards.

Non-medical masks should be washed frequently and handled carefully, so as not to contaminate other items.

If the layers of fabrics look noticeably worn out, discard the mask.

Clothing fabrics used to make masks should be checked for the highest permitted washing temperature. If instructions for washing are indicated on the clothing label, verify if washing in warm or hot water is tolerated. Select washable fabrics that can be washed. Wash in warm hot water, 60°C, with soap or laundry detergent. Non-woven polypropylene (PP) spunbond may be washed at high temperatures, up to 125°C.(72) Natural fibres may resist high temperature washes and ironing. Wash the mask delicately (without too much friction, stretching or wringing) if nonwoven materials (e.g. spunbond) are used. The combination of non-woven PP spunbond and cotton can tolerate high temperatures; masks made of these combinations may be steamed or boiled.

Where hot water is not available, wash mask with soap/detergent at room temperature water, followed by either i) boiling mask for one minute OR ii) soak mask in 0.1% chlorine for one minute then thoroughly rinse mask with room temperature water, to avoid any toxic residual of chlorine.

WHO is collaborating with research and development partners and the scientific community engaged in textile engineering and fabric design to facilitate a better understanding of the effectiveness and efficiency of non-medical masks. WHO urges countries that have issued recommendations on the use of both medical and non-medical masks by healthy people in community settings to conduct research on this important topic. Such research needs to look at whether SARS-CoV-2 particles can be expelled through non-medical masks of poor quality worn by a person with symptoms of COVID-19 while that person is coughing, sneezing or speaking. Research is also needed on non-medical mask use by children and other medically challenging persons and settings as mentioned above.

Table 4 provides a summary of guidance and practical considerations on the composition, construction and management of non-medical masks.

Table 4. Summary guidance and practical considerations for non-medical mask production and management

Guidance and practical considerations
Fabric selection:
Choose materials that capture particles and droplets but remain easy to breathe through.
Avoid stretchy material for making masks as they provide lower filtration efficiency during use and are sensitive to washing at high temperatures.
Fabrics that can support high temperatures (60° or more) are preferable.
Construction:
A minimum of three layers is required, depending on the fabric used: an inner layer touching the mouth and an outer layer that is exposed to the environment.
Choose water-absorbing (hydrophilic) materials or fabrics for the internal layers, to readily absorb droplets, combined with an external synthetic material that does not easily absorb liquid (hydrophobic).
Mask management:
Masks should only be used by one person.
All masks should be changed if soiled or wet; a soiled or wet mask should not be worn for an extended period of time.
Non-medical masks should be washed frequently and handled carefully, so as not to contaminate other items.
Clothing fabrics used to make masks should be checked for the highest permitted washing temperature, which is indicated on the clothing label.
Non-woven polypropylene (PP) spunbond may be washed at high temperature, up to 140°C.
The combination of non-woven PP spunbond and cotton can tolerate high temperatures; masks made of these combinations may be steamed or boiled.
Where hot water is not available, wash mask with soap/detergent at room temperature water, followed by either i) boiling mask for one minute OR ii) soak mask in 0.1% chlorine for one minute then thoroughly rinse mask with room temperature water, to avoid any toxic residual of chlorine.

3. Alternatives to non-medical masks for the general public

In the context of non-medical mask shortage, face shields may be considered as an alternative noting that they are inferior to mask with respect to prevention of droplet transmission. If face shields are to be used, ensure proper design to cover the sides of the face and below the chin. In addition, they may be easier to wear for individuals with limited compliance with medical masks (such as those with mental health disorders, developmental disabilities, deaf and hard of hearing community and children).

Guidance on the use of medical masks for the care of COVID-19 patients at home

WHO provides guidance on how to care for patients with confirmed and suspected COVID-19 at home when care in a health facility or other residential setting is not possible.(4) Home care may be considered when inpatient care or isolation in non-traditional settings is unavailable or unsafe (e.g. capacity is limited and resources are unable to meet the demand for care services). If feasible, a trained health worker should conduct an assessment to verify whether the patient and the family are able to comply with recommended measures for home-care isolation (e.g. hand hygiene, respiratory hygiene, environmental cleaning, limitations on movement around or from the house) and to address safety concerns (e.g. accidental ingestion of and fire hazards associated with using alcohol-based handrubs). Specific IPC guidance for home care should be followed. (4)

Persons with suspected COVID-19 or mild COVID-19 symptoms and no risk factors should:

- be isolated in a medical facility if confirmed, or self-isolate at home if isolation in a medical or other designated facility is not indicated or not possible;
- perform hand and respiratory hygiene frequently;
- keep a distance of at least 1 metre (3.3 feet) from other people;
- **wear a medical mask** as much as possible; the mask should be changed at least once daily. Persons who cannot tolerate a medical mask should rigorously apply respiratory hygiene (i.e. cover mouth and nose with a disposable paper tissue when coughing or sneezing and dispose of it immediately after use or use a bent elbow procedure and then perform hand hygiene);
- limit movement and minimize shared space;
- avoid contaminating surfaces with saliva, sputum or respiratory secretions;
- improve airflow and ventilation in their living space by opening windows and doors as much as possible;
- ensure adequate cleaning and disinfection of touch surfaces, near where the patient is being cared for, such as bedside tables, bedframes, and other bedroom furniture; electronic touchscreens, keyboards, and controls; and bathroom fixtures.

Caregivers or those sharing living space with people with suspected COVID-19 or with mild COVID-19 symptoms should:

- perform hand hygiene according to the 5 Moments of Hand Hygiene,(80) using an alcohol-based handrub if hands are not visibly dirty or soap and water when hands are visibly dirty;

- keep a distance of at least 1 m from the affected person when possible;
- **wear a medical mask** when in the same room as the affected person;
- dispose of any material contaminated with respiratory secretions (disposable tissues) immediately after use and then perform hand hygiene;
- improve airflow and ventilation in the living space by opening windows as much as possible;
- ensure adequate cleaning and disinfection of touch surfaces in the patient's room, such as bedside tables, bedframes and other bedroom furniture; electronic touchscreens, keyboards, and controls; and bathroom fixtures.

Guidance on mask management

For any type of mask, appropriate use and disposal are essential to ensure that they are as effective as possible and to avoid any increase in transmission.

WHO offers the following guidance on the correct use of masks, derived from best practices in health care settings:

- perform hand hygiene before putting on the mask;
- place the mask carefully, ensuring it covers the mouth and nose, adjust to the nose bridge, and tie it securely to minimize any gaps between the face and the mask;
- avoid touching the mask while wearing it;
- remove the mask using the appropriate technique: do not touch the front of the mask but untie it from behind.
- after removal or whenever a used mask is inadvertently touched, clean hands with an alcohol-based handrub, or soap and water if hands are visibly dirty;
- replace masks as soon as they become damp with a new clean, dry mask;
- do not re-use single-use masks;
- discard single-use masks after each use and dispose of them immediately upon removal.

WHO continues to monitor the situation closely for any changes that may affect this interim guidance. Should any factors change, WHO will issue a further update. Otherwise, this interim guidance document will expire 2 years after the date of publication.

References

1. Infection prevention and control of epidemic and pandemic-prone respiratory infections in health care. Geneva: World Health Organization; 2014 (https://www.who.int/csr/bioriskreduction/infection_control/publication/en/, accessed 13 May 2020).
2. Infection prevention and control during health care when COVID-19 is suspected: interim guidance. Geneva: World Health Organization; 2020 ([https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-\(ncov\)-infection-is-suspected-20200125](https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125), accessed 4 June 2020).
3. Infection prevention and control for long-term care facilities in the context of COVID-19: interim guidance. Geneva: World Health Organization; 2020 (<https://www.who.int/publications-detail/infection-prevention-and-control-for-long-term-care-facilities-in-the-context-of-covid-19>, accessed 4 June 2020).
4. Home care for patients with COVID-19 presenting with mild symptoms and management of contacts: interim guidance. Geneva: World Health Organization; 2020 (<https://apps.who.int/iris/handle/10665/331133>, accessed 4 June 2020).
5. Liu J, Liao X, Qian S, Yuan J, Wang F, Liu Y, et al. Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, Shenzhen, China, 2020. *Emerg Infect Dis.* 2020;26(6):1320-3.
6. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet.* 2020;395(10223):514-23.
7. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med.* 2020;382(13):1199-207.
8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395(10223):497-506.
9. Burke RM, Midgley CM, Dratch A, Fenstersheib M, Haupt T, Holshue M, et al. Active Monitoring of Persons Exposed to Patients with Confirmed COVID-19 - United States, January-February 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(9):245-6.
10. Coronavirus disease 2019 (COVID-19) Situation Report – 73. Geneva: World Health Organization; 2020 (https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200402-sitrep-73-covid-19.pdf?sfvrsn=5ae25bc7_6, accessed 4 June 2020).
11. Cheng VCC, Wong SC, Chen JHK, Yip CCY, Chuang VWM, Tsang OTY, et al. Escalating infection control response to the rapidly evolving epidemiology of the coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 in Hong Kong. *Infect Control Hosp Epidemiol.* 2020;41(5):493-8.
12. Ong SWX, Tan YK, Chia PY, Lee TH, Ng OT, Wong MSY, et al. Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. *JAMA.* 2020.
13. Guo ZD, Wang ZY, Zhang SF, Li X, Li L, Li C, et al. Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020. *Emerg Infect Dis.* 2020;26(7).
14. Chia PY, Coleman KK, Tan YK, Ong SWX, Gum M, Lau SK, et al. Detection of air and surface contamination by SARS-CoV-2 in hospital rooms of infected patients. *Nat Commun.* 2020;11(1):2800.

15. Santarpia JL, Rivera DN, Herrera V, Morwitzer MJ, Creager H, Santarpia GW, et al. Transmission Potential of SARS-CoV-2 in Viral Shedding Observed at the University of Nebraska Medical Center. medRxiv. [preprint]. In press 2020.
16. Faridi S, Niazi S, Sadeghi K, Naddafi K, Yavarian J, Shamsipour M, et al. A field indoor air measurement of SARS-CoV-2 in the patient rooms of the largest hospital in Iran. *Sci Total Environ.* 2020;725:138401.
17. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. *N Engl J Med.* 2020;382(16):1564-7.
18. Fears A, Klimstra W Duprex P, et al. Comparative dynamic aerosol efficiencies of three emergent coronaviruses and the unusual persistence of SARS-CoV-2 in aerosol suspensions (preprint). MedRxiv. [preprint]. (<https://www.medrxiv.org/content/10.1101/2020.04.13.20063784v1>, accessed 4 June 2020)
19. Symptom-Based Strategy to Discontinue Isolation for Persons with COVID-19. Atlanta: Centers for Disease Control and Prevention; (<https://www.cdc.gov/coronavirus/2019-ncov/community/strategy-discontinue-isolation.html>, accessed 4 June 2020).
20. Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature.* 2020;581(7809):465-9.
21. Yu P, Zhu J, Zhang Z, Han Y. A Familial Cluster of Infection Associated With the 2019 Novel Coronavirus Indicating Possible Person-to-Person Transmission During the Incubation Period. *J Infect Dis.* 2020;221(11):1757-61.
22. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med.* 2020;172(9):577-82.
23. Kimball A, Hatfield KM, Arons M, James A, Taylor J, Spicer K, et al. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King County, Washington, March 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(13):377-81.
24. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med.* 2020;26(5):672-5.
25. Byambasuren, O., Cardona, M., Bell, K., Clark, J., McLaws, M.-L., Glasziou, P., 2020. Estimating the extent of true asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis (preprint). *Infectious Diseases (except HIV/AIDS).* MedRxiv. [preprint]. (<https://www.medrxiv.org/content/10.1101/2020.05.10.20097543v1>, accessed 4 June 2020)
26. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. *N Engl J Med.* 2020;382(22):2081-90.
27. Luo, L., Liu, D., Liao, X., Wu, X., Jing, Q., Zheng, J., et al., 2020. Modes of contact and risk of transmission in COVID-19 among close contacts (preprint). MedRxiv. [preprint]. (<https://www.medrxiv.org/content/10.1101/2020.03.24.20042606v1>, accessed 4 June 2020)
28. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Sci China Life Sci.* 2020;63(5):706-11.
29. Huang R, Xia J, Chen Y, Shan C, Wu C. A family cluster of SARS-CoV-2 infection involving 11 patients in Nanjing, China. *Lancet Infect Dis.* 2020;20(5):534-5.
30. Pan X, Chen D, Xia Y, Wu X, Li T, Ou X, et al. Asymptomatic cases in a family cluster with SARS-CoV-2 infection. *Lancet Infect Dis.* 2020;20(4):410-1.
31. Wang Y, Tong J, Qin Y, Xie T, Li J, Li J, et al. Characterization of an asymptomatic cohort of SARS-COV-2 infected individuals outside of Wuhan, China. *Clin Infect Dis.* 2020.
32. Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic Transmission of SARS-CoV-2 - Singapore, January 23-March 16, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(14):411-5.
33. Cheng HY, Jian SW, Liu DP, Ng TC, Huang WT, Lin HH, et al. Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset. *JAMA Intern Med.* 2020.
34. European Standards. UNE EN 14683:2019+AC:2019. Medical Face Masks -Requirements and Test Methods. 2019; (<https://www.en-standard.eu/une-en-14683-2019-ac-2019-medical-face-masks-requirements-and-test-methods/>, accessed 4 June 2020)
35. F23 Committee, n.d. Specification for Performance of Materials Used in Medical Face Masks. ASTM International. (<https://doi.org/10.1520/F2100-19E01>, accessed 4 June 2020).
36. National Institute for Occupational Safety and Health (NIOSH). NIOSH Guide to the Selection and Use of Particulate Respirators. Department of Health and Human Services (DHHS)NIOSH publication number 96-101, 1996. (<http://www.cdc.gov/niosh/userguid.html>, accessed 4 June 2020).
37. CEN, E., 2001. 149: 2001 norm: Respiratory protective devices-Filtering half masks to protect against particles-Requirements, testing, marking. European Committee for Standardization. (<https://shop.bsigroup.com/ProductDetail?pid=00000000030178264>, accessed 4 June 2020).
38. Surviving Sepsis Campaign (SSC). Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Mount Prospect: Society for Critical Care Medicine; 2020 (<https://www.sccm.org/SurvivingSepsisCampaign/Guidelines/COVID-19>, accessed 4 June 2020).

39. Guidelines on Infection Prevention for Health Care Personnel Caring for Patients with Suspected or Known COVID-19. Arlington: Infectious Disease Society of America; 2020 (<https://www.idsociety.org/COVID19guidelines/ip>, accessed 4 June 2020).
40. Long Y, Hu T, Liu L, Chen R, Guo Q, Yang L, et al. Effectiveness of N95 respirators versus surgical masks against influenza: A systematic review and meta-analysis. *J Evid Based Med.* 2020;13(2):93-101.
41. Jefferson, T., Jones, M., Al Ansari, L.A., Bawazeer, G., Beller, E., Clark, et al., 2020. Physical interventions to interrupt or reduce the spread of respiratory viruses. Part 1 - Face masks, eye protection and person distancing: systematic review and meta-analysis. *MedRxiv*. [preprint]. (<https://www.medrxiv.org/content/10.1101/2020.03.30.20047217v2>, accessed 4 June 2020)
42. Chu, D.K., Akl, E.A., Duda, S., Solo, K., Yaacoub, S., Schünemann, et al., 2020. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet* S0140673620311429. ([https://doi.org/10.1016/S0140-6736\(20\)31142-9](https://doi.org/10.1016/S0140-6736(20)31142-9), accessed 4 June 2020).
43. Foo CC, Goon AT, Leow YH, Goh CL. Adverse skin reactions to personal protective equipment against severe acute respiratory syndrome--a descriptive study in Singapore. *Contact Dermatitis.* 2006;55(5):291-4.
44. Radonovich LJ, Jr., Simberkoff MS, Bessesen MT, Brown AC, Cummings DAT, Gaydos CA, et al. N95 Respirators vs Medical Masks for Preventing Influenza Among Health Care Personnel: A Randomized Clinical Trial. *JAMA.* 2019;322(9):824-33.
45. Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages. Geneva: World Health Organization; 2020 ([https://www.who.int/publications-detail/rational-use-of-personal-protective-equipment-for-coronavirus-disease-\(covid-19\)-and-considerations-during-severe-shortages](https://www.who.int/publications-detail/rational-use-of-personal-protective-equipment-for-coronavirus-disease-(covid-19)-and-considerations-during-severe-shortages), accessed 4 June 2020).
46. The World Health Report 2006 - working together for health. Geneva: World Health Organization; 2006.
47. Klompas M, Morris CA, Sinclair J, Pearson M, Shenoy ES. Universal Masking in Hospitals in the Covid-19 Era. *N Engl J Med.* 2020;382(21):e63.
48. Zamora JE, Murdoch J, Simchison B, Day AG. Contamination: a comparison of 2 personal protective systems. *CMAJ.* 2006;175(3):249-54.
49. Kwon JH, Burnham CD, Reske KA, Liang SY, Hink T, Wallace MA, et al. Assessment of Healthcare Worker Protocol Deviations and Self-Contamination During Personal Protective Equipment Donning and Doffing. *Infect Control Hosp Epidemiol.* 2017;38(9):1077-83.
50. Al Badri F. Surgical mask contact dermatitis and epidemiology of contact dermatitis in healthcare workers. *Current Allergy & Clinical Immunology*, 30,3: 183 - 188. 2017.
51. Matusiak L, Szepietowska M, Krajewski P, Bialynicki-Birula R, Szepietowski JC. Inconveniences due to the use of face masks during the COVID-19 pandemic: a survey study of 876 young people. *Dermatol Ther.* 2020.
52. MacIntyre CR, Seale H, Dung TC, Hien NT, Nga PT, Chughtai AA, et al. A cluster randomised trial of cloth masks compared with medical masks in healthcare workers. *BMJ Open.* 2015;5(4):e006577.
53. Community-based health care, including outreach and campaigns, in the context of the COVID-19 pandemic. (<https://www.who.int/publications-detail/community-based-health-care-including-outreach-and-campaigns-in-the-context-of-the-covid-19-pandemic>, accessed 4 June 2020).
54. Canini L, Andreoletti L, Ferrari P, D'Angelo R, Blanchon T, Lemaitre M, et al. Surgical mask to prevent influenza transmission in households: a cluster randomized trial. *PLoS One.* 2010;5(11):e13998.
55. MacIntyre CR, Zhang Y, Chughtai AA, Seale H, Zhang D, Chu Y, et al. Cluster randomised controlled trial to examine medical mask use as source control for people with respiratory illness. *BMJ Open.* 2016;6(12):e012330.
56. Cowling BJ, Chan KH, Fang VJ, Cheng CK, Fung RO, Wai W, et al. Facemasks and hand hygiene to prevent influenza transmission in households: a cluster randomized trial. *Ann Intern Med.* 2009;151(7):437-46.
57. Barasheed O, Alfelali M, Mushta S, Bokhary H, Alshehri J, Attar AA, et al. Uptake and effectiveness of facemask against respiratory infections at mass gatherings: a systematic review. *Int J Infect Dis.* 2016;47:105-11.
58. Lau JT, Tsui H, Lau M, Yang X. SARS transmission, risk factors, and prevention in Hong Kong. *Emerg Infect Dis.* 2004;10(4):587-92.
59. Suess T, Remschmidt C, Schink SB, Schweiger B, Nitsche A, Schroeder K, et al. The role of facemasks and hand hygiene in the prevention of influenza transmission in households: results from a cluster randomised trial; Berlin, Germany, 2009-2011. *BMC Infect Dis.* 2012;12:26.
60. Wu J, Xu F, Zhou W, Feikin DR, Lin CY, He X, et al. Risk factors for SARS among persons without known contact with SARS patients, Beijing, China. *Emerg Infect Dis.* 2004;10(2):210-6.
61. Barasheed O, Almasri N, Badahdah AM, Heron L, Taylor J, McPhee K, et al. Pilot Randomised Controlled Trial to Test Effectiveness of Facemasks in Preventing Influenza-like Illness Transmission among Australian Hajj Pilgrims in 2011. *Infect Disord Drug Targets.* 2014;14(2):110-6.
62. Aiello AE, Murray GF, Perez V, Coulborn RM, Davis BM, Uddin M, et al. Mask use, hand hygiene, and seasonal influenza-like illness among young adults: a randomized intervention trial. *J Infect Dis.* 2010;201(4):491-8.
63. Aiello AE, Perez V, Coulborn RM, Davis BM, Uddin M, Monto AS. Facemasks, hand hygiene, and influenza among young adults: a randomized intervention trial. *PLoS One.* 2012;7(1):e29744.

64. Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, et al. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. *Clin Infect Dis*. 2020.
65. Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T. The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis. *Otolaryngol Head Neck Surg*. 2020;194599820926473.
66. McMichael TM, Currie DW, Clark S, Pogosjans S, Kay M, Schwartz NG, et al. Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington. *N Engl J Med*. 2020;382(21):2005-11.
67. Tay HS, Harwood R. Atypical presentation of COVID-19 in a frail older person. *Age Ageing*. 2020.
68. Coronavirus disease (COVID-19) advice for the public: When and how to use masks. Geneva: World Health Organization; 2020. (<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/when-and-how-to-use-masks>, accessed 4 June 2020).
69. Information Note COVID-19 and NCDs. Geneva: World Health Organization. 2020. (https://www.who.int/docs/default-source/inaugural-who-partners-forum/covid-19-and-ncds---final---corr7.pdf?sfvrsn=9b65e287_1&download=true, accessed 4 June 2020).
70. Public use of masks as source control during the COVID-19 pandemic: key considerations from social science. Geneva: World Health Organization; 2020. (unpublished, accessed 26 May 2020).
71. AFNOR. 2020. SPEC S76-001: Masque barrière. Guide d'exigence minimales, de méthode d'essais, de confection et d'usage. (<https://masques-barrieres.afnor.org/home/telechargement>, accessed 4 June 2020).
72. Liao L, Xiao W, Zhao M, Yu X, Wang H, Wang Q, et al. Can N95 Respirators Be Reused after Disinfection? How Many Times? *ACS Nano*. 2020;14(5):6348-56.
73. Jung, H., Kim, J.K., Lee, S., Lee, J., Kim, J., Tsai, P., et al., 2014. Comparison of Filtration Efficiency and Pressure Drop in Anti-Yellow Sand Masks, Quarantine Masks, Medical Masks, General Masks, and Handkerchiefs. *Aerosol Air Qual. Res.* 14, 991–1002. (<https://doi.org/10.4209/aaqr.2013.06.0201>, accessed 4 June 2020).
74. Rengasamy S, Eimer B, Shaffer RE. Simple respiratory protection--evaluation of the filtration performance of cloth masks and common fabric materials against 20-1000 nm size particles. *Ann Occup Hyg*. 2010;54(7):789-98.
75. Jang JY, Kim, S.W., . Evaluation of Filtration Performance Efficiency of Commercial Cloth Masks *Journal of Environmental Health Sciences (한국환경보건학회지)* Volume 41 Issue 3 / Pages203-215 / 2015. 2015.
76. Podgórski, A., Bałazy, A., Gradoń, L., 2006. Application of nanofibers to improve the filtration efficiency of the most penetrating aerosol particles in fibrous filters. *Chemical Engineering Science* 61, 6804–6815. (<https://doi.org/10.1016/j.ces.2006.07.022>, accessed 4 June 2020).
77. Zhao M, Liao L, Xiao W, Yu X, Wang H, Wang Q, et al. Household materials selection for homemade cloth face coverings and their filtration efficiency enhancement with triboelectric charging. *Nano Lett*. 2020.
78. Reusability of Facemasks During an Influenza Pandemic: Facing the Flu, 2006. National Academies Press, Washington, D.C. (<https://doi.org/10.17226/11637>, accessed 4 June 2020).
79. Lee SA, Hwang DC, Li HY, Tsai CF, Chen CW, Chen JK. Particle Size-Selective Assessment of Protection of European Standard FFP Respirators and Surgical Masks against Particles-Tested with Human Subjects. *J Healthc Eng*. 2016;2016.
80. Your 5 Moments for Hand Hygiene. Geneva: World Health Organization; 2020 (https://www.who.int/gpsc/5may/Your_5_Moments_For_Hand_Hygiene_Poster.pdf?ua=1, accessed 4 June 2020).

Acknowledgements

This document was developed based on advice by the Strategic and Technical Advisory Group for Infectious Hazards (STAG-IH), and in consultation with the following members of:

- 1) the WHO Health Emergencies Programme (WHE) Ad-hoc COVID-19 IPC Guidance Development Group (in alphabetical order):

Jameela Alsaman, Ministry of Health, Bahrain; Anucha Apisarntharak, Thammasat University Hospital, Thailand; Baba Aye, Public Services International, France; Gregory Built, UNICEF, United States of America (USA); Roger Chou, Oregon Health Science University, USA; May Chu, Colorado School of Public Health, USA; John Conly, Alberta Health Services, Canada; Barry Cookson, University College London, United Kingdom; Nizam Damani, Southern Health & Social Care Trust, United Kingdom; Dale Fisher, Goarn, Singapore; Joost Hopman, Radboud University Medical Center, The Netherlands; Mushtuq Husain, Institute of Epidemiology, Disease Control & Research, Bangladesh; Kushlani Jayatilleke, Sri Jayewardenapura General Hospital, Sri Lanka; Seto Wing Jong, School of Public Health, Hong Kong SAR, China; Souha Kanj, American University of Beirut Medical Center, Lebanon; Daniele Lantagne, Tufts University, USA; Fernanda Lessa, Centers for Disease Control and Prevention, USA; Anna Levin, University of São Paulo, Brazil; Ling Moi Lin, Sing Health, Singapore; Caline Mattar, World Health Professions Alliance, USA; Mary-Louise McLaws, University of New South Wales, Australia; Geeta Mehta, Journal of Patient Safety and Infection Control, India; Shaheen Mehtar, Infection Control Africa Network, South Africa; Ziad Memish, Ministry of Health, Saudi Arabia; Babacar Ndoye, Infection Control Africa Network, Senegal; Fernando Otaiza, Ministry of Health, Chile; Diamantis

Plachouras, European Centre for Disease Prevention and Control, Sweden; Maria Clara Padoveze, School of Nursing, University of São Paulo, Brazil; Mathias Pletz, Jena University, Germany; Marina Salvadori, Public Health Agency of Canada, Canada; Mitchell Schwaber, Ministry of Health, Israel; Nandini Shetty, Public Health England, United Kingdom; Mark Sobsey, University of North Carolina, USA; Paul Ananth Tambyah, National University Hospital, Singapore; Andreas Voss, Canisius-Wilhelmina Ziekenhuis, The Netherlands; Walter Zingg, University of Geneva Hospitals, Switzerland;

2) the WHO Health Emergencies Programme (WHE) Ad-hoc Experts Advisory Panel for Infection Prevention and Control (IPC) Preparedness, Readiness and Response to COVID-19, and other international experts including (in alphabetical order):

Mardjan Arvand, Robert Koch Institute Nordufer, Denmark; Elizabeth Bancroft, Centers for Disease Control and Prevention, USA; Gail Carson, ISARIC Global Support Centre, United Kingdom; Larry Chu, Stanford University School of Medicine, USA; Shan-Chwen Chang, National Taiwan University, Taiwan, Feng-Yee Chang, National Defense Medical Center, Taiwan, Steven Chu, Stanford University, USA; Yi Cui, Stanford University, USA; Jane Davies, Médecins Sans Frontières, The Netherlands; Katherine Defalco, Public Health Agency of Canada, Canada; Kathleen Dunn, Public Health Agency of Canada; Janine Goss, Public Health England, United Kingdom; Alison Holmes, Imperial College, United Kingdom; Paul Hunter, University of East Anglia, United Kingdom; Giuseppe Ippolito, Istituto Nazionale per le Malattie Infettive Lazzaro

Spallanzani, Italy; Marimuthu Kalisvar, Tan Tock Seng Hospital, Singapore; Dan Lebowitz, Hopitaux Universitaires de Geneve, Switzerland; Outi Lyytikäinen, Finland; Trish Perl, UT Southwestern, USA; F. Mauro Orsini, Ministry of Health, Santiago, Chile; Didier Pittet, University of Geneva Hospitals, and Faculty of Medicine, Geneva, Switzerland; Benjamin Park, Centers for Disease Control and Prevention, USA; Amy Price, Stanford University School of Medicine, USA; Supriya Sharma, Public Health Canada; Nalini Singh, The George Washington University, USA; Rachel Smith, Centers for Disease Control and Prevention, USA; Jorgen Stassinjns, Médecins Sans Frontières, The Netherlands; Sara Tomczyk, Robert Koch Institute, Germany.

The WHO Secretariat: Benedetta Allegranzi, Gertrude Avortri, Mekdim Ayana, Hanan Balkhy, April Baller, Elizabeth Barrera-Cancedda, Anjana Bhushan, Sylvie Briand, Alessandro Cassini, Giorgio Cometto, Ana Paula Coutinho Rehse, Carmem Da Silva, Nino Dal Dayanguirang, Sophie Harriet Dennis, Sergey Eremin, Dennis Nathan Ford, Jonas Gonseth-Garcia, Rebeca Grant, Tom Grein, Ivan Ivanov, Landry Kabego, Pierre Claver Kariyo, Ying Ling Lin, Ornella Lincetto, Madison Moon, Takeshi Nishijima, Kevin Babila Ousman, Pillar Ramon-Pardo, Paul Rogers, Nahoko Shindo, Alice Simniceanu, Valeska Stempliuk, Maha Talaat Ismail, Joao Paulo Toledo, Anthony Twywan, Maria Van Kerkhove, Vicky Willet, Masahiro Zakoji, Bassim Zayed.

© World Health Organization 2020. Some rights reserved. This work is available under the [CC BY-NC-SA 3.0 IGO](#) licence.

WHO reference number: [WHO/2019-nCov/IPC_Masks/2020.4](#)